Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kymera Therapeutics Inc.

www.kymeratx.com

Latest From Kymera Therapeutics Inc.

Nurix’s $120m Venture Round Will Bring Two Protein-Modulating Therapies To Clinic

Company’s technology harnesses E3 ligases to either degrade dysregulated proteins or inhibit a specific ligase to increase substrate protein levels for therapeutic benefit.

Financing Business Strategies

Finance Watch: Kymera Will Start Protein Degrader Clinical Trials With $102m VC Round

Private Company Edition: Kymera said it will take up to three programs into the clinic by next year. Also, three new life science funds recently launched, including a Gates Foundation-backed accelerator for COVID-19 treatments, and Cell Medica reemerges as Kuur with new funding for CAR-NKT therapies.

Financing Coronavirus COVID-19

Deal Watch: Another Delay For Roche/Spark, While FTC Ups AbbVie/Allergan Merger Scrutiny

Tender deadline for Roche acquisition of Spark pushed back to 30 October; 21.4% of Spark shares tendered so far. Vertex further diversifies with fourth deal of 2019 – an RNA-targeted collaboration with Ribometrix.

Deals M & A

Eisai Joins PROTAC Club Through New Oncology Collab

Japanese firm joins increasing global interest in PROTAC approach to cancer as it links with UK university for drug discovery collaboration.

Cancer Platform Technologies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Kymera Therapeutics Inc.
  • Senior Management
  • Nello Mainolfi, PhD, Pres. & CEO
    Bruce Jacobs, CFO
    Mark E Nuttall, PhD, CBO
    Jared Gollob, MD, CMO
  • Contact Info
  • Kymera Therapeutics Inc.
    300 Technology Sq., 2nd Fl.
    Cambridge, MA 02139
    USA
UsernamePublicRestriction

Register